Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

Abstract: A stabilized pharmaceutical dosage unit comprising tibolone, in an amount of from 0.1% to 10% by weight of the dosage unit, and a pharmaceutically acceptable carrier. The dosage unit is contained in a humid atmosphere of 50 to 70% relative humidity until administration.

Abstract: Polycyclic phthalazines, in particular 2-substituted maduraphthalazines (10,12,15,16-tetrahydroxy-8-methoxy-11-methyl-1,9,14-trioxo-1,2,6,7,9,14-h exahydronaphthaceno-1,2-g-phthalazines), of formula I and their use against gram-positive bacterial strains, particularly against multi-resistant staphylococci (MRSA) and against glycopeptide-resistant, for example vancomycin-resistant, enterococci. The polycyclic phthalazines are thus suitable for preparing anti-bacterially effective pharmaceutical compositions. In formula I, R.sup.1 is carboxyalkyl or carboxyaryl, and R.sup.2 and R.sup.3 represent H or acyl (for example CO-alkyl or COO-alkyl), with R.sup.1 being different from optionally substituted carboxyphenyl when R.sup.3 represents C.sub.1-8 alkanoyl. The invention also relates to salts, amides and esters of compounds of formula I.

Abstract: The present invention provides novel 2-decarboxy-2-hydroxymethyl-19-hydroxy-6-oxo-PGF.sub.1 compounds which are useful for pharmacological purposes, e.g., anti-asthmatic indications.